poisar

Stocks · News reference

Arcus Biosciences Q2 EPS $(0.72) Beats $(0.87) Estimate, Sales $41.000M Beat $23.405M Estimate

Aug 5, 2026, 8:08 PMBenzinga Newsdesk

Arcus Biosciences (NYSE:RCUS) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate of $(0.87) by 17.24 percent. This is a Infinity percent decrease over earnings of $0.00 per share

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

RCUS
Source
benzinga
Observed
Aug 5, 2026, 8:08 PM
Checked
Aug 5, 2026, 8:08 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  3. Jul 22, 2026, 8:48 PMBenzinga Newsdesk

    Arcus Biosciences Announces A Clinical Supply Agreement With AVEO Oncology To Evaluate Casdatifan; Agreement Supports A New Randomized Cohort Within The ARC-20 Study Evaluating Investigational Casdatifan Plus Tivozanib Versus Tivozanib Alone In Patients Who Received Prior HIF-2α-inhibitor Therapy; Enrollment Expected To Begin In Q4 2026

    This agreement supports a new randomized cohort within the ARC-20 study evaluating investigational casdatifan plus tivozanib versus tivozanib alone in patients who received prior HIF-2α-inhibitor therapyEnrollment is

    Read original at benzinga
    RCUS